[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Pharmacology](https://durgical.com/en/pharmacology/) › [Ebola monoclonal antibodies](https://durgical.com/en/pharmacology/classes/ebola-monoclonal-antibodies/) › Atoltivimab + maftivimab + odesivimab

[Pharmacology](https://durgical.com/en/pharmacology/) · [Ebola monoclonal antibodies](https://durgical.com/en/pharmacology/classes/ebola-monoclonal-antibodies/)

# Atoltivimab + maftivimab + odesivimab

A three-antibody combination against the Ebola virus glycoprotein. WHO strongly recommends it for Ebola virus disease.

Updated 2026-11-01

- Class: [Ebola monoclonal antibodies](https://durgical.com/en/pharmacology/classes/ebola-monoclonal-antibodies/)
- Target: Zaire ebolavirus surface glycoprotein (GP)
- WHO Model List of Essential Medicines

Also called: REGN-EB3

## Mechanism of action

Three human IgG1 monoclonal antibodies that bind three non-overlapping sites on the Ebola virus glycoprotein at the same time. Maftivimab neutralizes the virus and blocks its entry into cells; odesivimab does not neutralize but recruits immune effector functions (antibody-dependent cellular cytotoxicity); atoltivimab does both. Using three antibodies makes viral escape less likely.

- Three antibodies bind different sites on the glycoprotein
- Virus attachment and membrane fusion are blocked
- Infected cells are marked for immune killing
- Viral load falls; survival improves when given early

## Pharmacokinetics

**Absorption**
Intravenous infusion

**Elimination**
Like other IgG antibodies, slow catabolism over weeks

## Indications

- Ebola virus disease caused by Zaire ebolavirus, in adults and children [Viral haemorrhagic fevers (Ebola and others) →](https://durgical.com/en/conditions/viral-haemorrhagic-fevers/)

## Adverse effects

### Common

- Fever and chills
- Fast heart rate and fast breathing
- Vomiting

### Serious (rare, important)

- Hypersensitivity reactions, including infusion-associated events, which can be life-threatening

## Contraindications

- Severe hypersensitivity to any of the three antibodies

## Key interactions

**Live Ebola (Zaire) vaccine**
May reduce the vaccine's efficacy; live vaccination is avoided at the same time

## What is monitored

- Vital signs during and after the infusion
- Fluid balance, electrolytes and kidney function as part of supportive care

## Administration and safety

- Single intravenous infusion
- Given in a treatment centre with full infection prevention and control precautions

## Nursing care

- Use full personal protective equipment
- Watch for infusion reactions
- Continue optimized supportive care, including treatment of co-infections such as malaria

## Pregnancy and breastfeeding

Ebola is life-threatening for mother and fetus, and treatment is not withheld because of pregnancy; the antibodies can cross the placenta.

## Memory aid

REGN-EB3: «three keys on one lock» (three antibodies on the glycoprotein).

## Test yourself

Think of the answer, then tap the question to see it.

## How many antibodies does this combination contain?

Three: atoltivimab, maftivimab and odesivimab.

## Which of the three antibodies is the neutralizing one?

Maftivimab (atoltivimab also neutralizes; odesivimab acts through immune effector functions).

## What trial supported the use of this combination?

The PALM randomized trial in the Democratic Republic of the Congo (2018–2020).

[Add to my cards (3)](https://durgical.app/estudiar/?add=/en/pharmacology/atoltivimab-maftivimab-odesivimab/)

## Related drugs

- [Ansuvimab](https://durgical.com/en/pharmacology/ansuvimab/)

## Related conditions

- [Viral haemorrhagic fevers (Ebola and others)](https://durgical.com/en/conditions/viral-haemorrhagic-fevers/)

[← Back to the class: Ebola monoclonal antibodies](https://durgical.com/en/pharmacology/classes/ebola-monoclonal-antibodies/)

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: [Ebola disease](https://www.who.int/news-room/fact-sheets/detail/ebola-disease) (World Health Organization, 2025); Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed., ch. 62 (McGraw Hill, 2023).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/pharmacology/atoltivimab-maftivimab-odesivimab/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/pharmacology/atoltivimab-maftivimab-odesivimab/